Biotech and Life Sciences Business Opportunities in Asia via the Hong Kong Platform

Event Details

Biotech and Life Sciences Business Opportunities in Asia
via the Hong Kong Platform

Summary

This event focuses on the specific benefits and opportunities in Hong Kong-based funding and partnership for Canadian companies in the Biotech and Life Sciences sectors. It will also convey brand awareness of the Office for Attracting Strategic Enterprises (OASES) proposition, along with the tactical advantages of considering Hong Kong as a base of operations.

In addition, the Hong Kong Trade Development Council (HKTDC) will discuss the HKCBA Mission to Asia Summit on Global Health + HK Int’l Medical and Healthcare Fair 2025. Notably, 34 Canadian delegates from 27 organizations who attended last year, benefiting from Canada Pavilion organized by the Consulate General of Canada in Hong Kong.

Join us to learn from case studies presented by Eric Cardinal (M&A Club // Medcom Xchange) and Emma Zhu (Bio-K) and discover why companies such as AstraZeneca; Yuanhua Robotics; Tigermed; Bio-K, Land Art and dozens more are already using Hong Kong as their gateway to Asia or planning to establish a presence there and seize this impactful opportunity to expand their operations toward Asia.

Who should attend

Companies in Life and Health Technology, specifically: Pharmaceutical; Healthcare; Medical devices and Biotechnology (Advanced Therapies, Diagnostics, Bioinformatics)
CEO or investor-level executives
Companies aiming for expansion and/or series ''A'' funding and beyond
Companies seeking commercialization, investment, strategic partnerships, and product or clinical trials

Speakers

	Dr. Maggie Lo Palmer Head of Life Sciences OASES
	Regina Lai Regional Director, Americas HKTDC
	Eric Cardinal Senior Vice-President // CFO M&A Club // Medcom Xchange
	Emma Zhu Sales And Marketing Ambassador Bio-K+ International Inc.